XML 41 R26.htm IDEA: XBRL DOCUMENT

Restructuring	12 Months Ended
Restructuring	Dec. 31, 2022
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring In June 2022, the Company began a strategic realignment to focus resources on its ulixacaltamide, PRAX-562, PRAX-222 and PRAX-628 product candidates, as well as its preclinical programs across our Cerebrum™ and Solidus™ platforms, which resulted in a reduction of the Company’s workforce. The Company incurred $1.0 million of costs related to the realignment, of which $0.6 million has been recognized in research and development expenses and $0.4 million has been recognized in general and administrative expenses in the consolidated statement of operations during the year ended December 31, 2022. These costs relate to employee severance, benefits and related costs. The Company does not expect to incur any additional significant costs related to the strategic realignment. As of December 31, 2022, all costs related to the strategic realignment have been paid.